Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.43USD
3:59pm EST
Change (% chg)

$-0.03 (-6.50%)
Prev Close
$0.46
Open
$0.48
Day's High
$0.48
Day's Low
$0.42
Volume
159,023
Avg. Vol
97,183
52-wk High
$2.80
52-wk Low
$0.42

Select another date:

BRIEF-Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®

* TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

BRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium

* TROVAGENE PRESENTS DATA SHOWING SENSITIVITY OF TRIPLE NEGATIVE BREAST CANCER (TNBC) CELL LINES TO PCM-075 AND SYNERGY WITH ZYTIGA® AT SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) Source text for Eikon: Further company coverage:

BRIEF-Trovagene Inc updates on clinical trial for PCM-075

* Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075

BRIEF-TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12

* ‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​ Source text: (http://bit.ly/2hgteK4) Further company coverage:

BRIEF-Trovagene files for offering of up to $17.5 mln- SEC filing

* Trovagene Inc files for offering of up to $17.5 million - SEC filing Source text: (http://bit.ly/2zOQs1P) Further company coverage:

BRIEF-Trovagene's PCM-075 demonstrates Synergy with Zytiga

* Trovagene Inc - ‍announced positive data from preclinical research demonstrating synergy of PCM-075 in combination with abiraterone (Zytiga)​

BRIEF-Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075

* Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML)

BRIEF-Trovagene files for offering of upto sale 4.64 mln shares of common stock by the selling stockholders‍​

* Trovagene Inc files for offering of up to sale 4.64 million shares of common stock by the selling stockholders‍​ - SEC Filing Source text: (http://bit.ly/2fELxf1) Further company coverage:

BRIEF-Trovagene appoints Athena Countouriotis to its board of directors

* Trovagene strengthens board of directors with appointment of oncology development veteran Dr. Athena Countouriotis Source text for Eikon: Further company coverage:

BRIEF-Trovagene reports positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor with investigational flt3 inhibitor

* Trovagene's plk1 inhibitor pcm-075, in preclinical aml data, significantly enhances the efficacy of a flt3 inhibitor in combination therapy

Select another date: